64 related articles for article (PubMed ID: 15581628)
1. Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation.
Ibañez C; Blanes-Mira C; Fernández-Ballester G; Planells-Cases R; Ferrer-Montiel A
FEBS Lett; 2004 Dec; 578(1-2):121-7. PubMed ID: 15581628
[TBL] [Abstract][Full Text] [Related]
2. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.
Baldwin MR; Bradshaw M; Johnson EA; Barbieri JT
Protein Expr Purif; 2004 Sep; 37(1):187-95. PubMed ID: 15294297
[TBL] [Abstract][Full Text] [Related]
3. Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A.
Kadkhodayan S; Knapp MS; Schmidt JJ; Fabes SE; Rupp B; Balhorn R
Protein Expr Purif; 2000 Jun; 19(1):125-30. PubMed ID: 10833399
[TBL] [Abstract][Full Text] [Related]
4. Substrate recognition strategy for botulinum neurotoxin serotype A.
Breidenbach MA; Brunger AT
Nature; 2004 Dec; 432(7019):925-9. PubMed ID: 15592454
[TBL] [Abstract][Full Text] [Related]
5. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate.
Fu Z; Chen S; Baldwin MR; Boldt GE; Crawford A; Janda KD; Barbieri JT; Kim JJ
Biochemistry; 2006 Jul; 45(29):8903-11. PubMed ID: 16846233
[TBL] [Abstract][Full Text] [Related]
6. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates.
Bade S; Rummel A; Reisinger C; Karnath T; Ahnert-Hilger G; Bigalke H; Binz T
J Neurochem; 2004 Dec; 91(6):1461-72. PubMed ID: 15584922
[TBL] [Abstract][Full Text] [Related]
7. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
8. Thermal stabilization of the catalytic domain of botulinum neurotoxin E by phosphorylation of a single tyrosine residue.
Blanes-Mira C; Ibañez C; Fernández-Ballester G; Planells-Cases R; Pérez-Payá E; Ferrer-Montiel A
Biochemistry; 2001 Feb; 40(7):2234-42. PubMed ID: 11329292
[TBL] [Abstract][Full Text] [Related]
9. [Mechanisms of action of botulinum toxins and neurotoxins].
Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol.
Cai S; Sarkar HK; Singh BR
Biochemistry; 1999 May; 38(21):6903-10. PubMed ID: 10346912
[TBL] [Abstract][Full Text] [Related]
11. Increased tyrosine phosphorylation of PSD-95 by Src family kinases after brain ischaemia.
Du CP; Gao J; Tai JM; Liu Y; Qi J; Wang W; Hou XY
Biochem J; 2009 Jan; 417(1):277-85. PubMed ID: 18721130
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins.
Ferrer-Montiel AV; Canaves JM; DasGupta BR; Wilson MC; Montal M
J Biol Chem; 1996 Aug; 271(31):18322-5. PubMed ID: 8702470
[TBL] [Abstract][Full Text] [Related]
13. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex.
Silvaggi NR; Wilson D; Tzipori S; Allen KN
Biochemistry; 2008 May; 47(21):5736-45. PubMed ID: 18457419
[TBL] [Abstract][Full Text] [Related]
14. Hemagglutinin-33 of type A botulinum neurotoxin complex binds with synaptotagmin II.
Zhou Y; Foss S; Lindo P; Sarkar H; Singh BR
FEBS J; 2005 Jun; 272(11):2717-26. PubMed ID: 15943806
[TBL] [Abstract][Full Text] [Related]
15. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain.
Chaddock JA; Purkiss JR; Alexander FC; Doward S; Fooks SJ; Friis LM; Hall YH; Kirby ER; Leeds N; Moulsdale HJ; Dickenson A; Green GM; Rahman W; Suzuki R; Duggan MJ; Quinn CP; Shone CC; Foster KA
Mov Disord; 2004 Mar; 19 Suppl 8():S42-7. PubMed ID: 15027053
[TBL] [Abstract][Full Text] [Related]
16. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition.
Lai H; Feng M; Roxas-Duncan V; Dakshanamurthy S; Smith LA; Yang DC
Arch Biochem Biophys; 2009 Nov; 491(1-2):75-84. PubMed ID: 19772855
[TBL] [Abstract][Full Text] [Related]
17. High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain.
Li L; Singh BR
Protein Expr Purif; 1999 Dec; 17(3):339-44. PubMed ID: 10600450
[TBL] [Abstract][Full Text] [Related]
18. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc.
Kalandakanond S; Coffield JA
J Pharmacol Exp Ther; 2001 Mar; 296(3):980-6. PubMed ID: 11181932
[TBL] [Abstract][Full Text] [Related]
19. Role of EGF-induced tyrosine phosphorylation of reggie-1/flotillin-2 in cell spreading and signaling to the actin cytoskeleton.
Neumann-Giesen C; Fernow I; Amaddii M; Tikkanen R
J Cell Sci; 2007 Feb; 120(Pt 3):395-406. PubMed ID: 17213334
[TBL] [Abstract][Full Text] [Related]
20. Suppression of the phosphorylation of receptor tyrosine phosphatase-alpha on the Src-independent site tyrosine 789 by reactive oxygen species.
Hao Q; Rutherford SA; Low B; Tang H
Mol Pharmacol; 2006 Jun; 69(6):1938-44. PubMed ID: 16505154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
